KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Assets (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Non-Current Assets for 16 consecutive years, with $162000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 96.31% to $162000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $780000.0 through Dec 2025, down 97.96% year-over-year, with the annual reading at $162000.0 for FY2025, 96.31% down from the prior year.
  • Non-Current Assets hit $162000.0 in Q4 2025 for Arbutus Biopharma, down from $268000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $64.2 million in Q1 2022 to a low of $148000.0 in Q2 2025.
  • Historically, Non-Current Assets has averaged $24.9 million across 5 years, with a median of $15.7 million in 2023.
  • Biggest five-year swings in Non-Current Assets: soared 621.19% in 2022 and later plummeted 98.75% in 2025.
  • Year by year, Non-Current Assets stood at $43.8 million in 2021, then rose by 1.04% to $44.3 million in 2022, then plummeted by 72.06% to $12.4 million in 2023, then tumbled by 64.51% to $4.4 million in 2024, then crashed by 96.31% to $162000.0 in 2025.
  • Business Quant data shows Non-Current Assets for ABUS at $162000.0 in Q4 2025, $268000.0 in Q3 2025, and $148000.0 in Q2 2025.